- 作者: Li-Tzu Wang, Chiao-Hsuan Ting, Men-Luh Yen, Ko-Jiunn Liu, Huey-Kang Sytwu, Kenneth K. Wu and B. Linju Yen
- 作者服務機構: 1. Regenerative Medicine Research Group, Institute of Cellular & System Medicine, National Health Research Institutes (NHRI), 35 Keyan Road, Zhunan 35053, Taiwan 2. Graduate Institute of Life Sciences, National Defense Medical Center (NDMC), Taiwan
- 中文摘要: --
- 英文摘要: Human mesenchymal stem cells (MSCs) are multilineage somatic progenitor/stem cells that have been shown to possess immunomodulatory properties in recent years. Initially met with much skepticism, MSC immunomodulation has now been well reproduced across tissue sources and species to be clinically relevant. This has opened up the use of these versatile cells for application as 3rd party/allogeneic use in cell replacement/tissue regeneration, as well as for immune- and inflammation-mediated disease entities. Most surprisingly, use of MSCs for in immune-/inflammation-mediated diseases appears to yield more efficacy than for regenerative medicine, since engraftment of the exogenous cell does not appear necessary. In this review, we focus on this non-traditional clinical use of a tissue-specific stem cell, and highlight important findings and trends in this exciting area of stem cell therapy.
- 中文關鍵字: --
- 英文關鍵字: Mesenchymal stem cells, Human, Immunomodulation, Inflammation, Clinical trials, Autoimmune disease, Organ transplantation and rejection, Stem cell therapy